Poniard Pharmaceuticals(OTC) PARD

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing innovative cancer treatments. The company’s flagship product candidate, Picoplatin, is a platinum-based therapy targeting various cancer types, including small cell lung, colorectal, prostate, and ovarian cancers.

Products and Services

• Picoplatin, a platinum-based therapy for multiple cancer types
• Clinical trials for various cancer indications
• Research and development in oncology therapeutics

Growth Outlook

• Ongoing Phase III SPEAR trial for small cell lung cancer
• Exploration of Picoplatin in metastatic colorectal cancer
• Potential for oral formulation of Picoplatin in solid tumors

Financial Highlights

• Recent quarterly net income of -$3.77 million
• Cash and cash equivalents of $1.98 million as of September 30, 2011
• Current ratio of 3.23 indicates strong liquidity position

Poniard Pharmaceuticals, Inc. has made significant strides in the biopharmaceutical sector, particularly in oncology. The company is advancing its lead product, Picoplatin, through various clinical trials, which could position it favorably in the competitive cancer treatment market. The ongoing Phase III trial and additional studies for other cancer types highlight the potential for future growth and market entry. Financially, the company has faced challenges, as indicated by the recent net income figures. However, the liquidity position remains robust, with a current ratio of 3.23, suggesting that the company can meet its short-term obligations. The cash reserves, while limited, provide a foundation for continued research and development efforts. Overall, Poniard Pharmaceuticals, Inc. presents an intriguing opportunity for investors interested in the biotechnology sector, particularly in innovative cancer therapies.